News News Select Year All Years 2026 (17) 2025 (34) 2024 (29) 2023 (30) 2022 (33) 2021 (27) 2020 (34) 2019 (32) 2018 (42) 2017 (35) 2016 (43) 2015 (53) 2014 (26) 2013 (21) 2012 (16) 2011 (6) 2010 (4) 2009 (5) 2007 (1) 2006 (1) Search News Found 489 Results Page 47 of 49« First«...102030...4546474849» August 2, 2012 DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults July 26, 2012 Half Year 2012 results and R&D highlights: DBV Technologies on track July 19, 2012 DBV Technologies welcomes Mr. Stef Koppelman as its new General Scientific Advisor June 18, 2012 DBV Technologies presents detailed results of a clinical study showing that VIASKIN® is safe and well-tolerated by peanut-allergic patients at the EAACI congress June 18, 2012 Positive interim clinical data in peanut allergic children treated with VIASKIN PEANUT June 6, 2012 DBV Technologies’ June 6th 2012 Ordinary Meeting of Shareholders May 31, 2012 Professor Hugh Sampson joins Scientific Advisory Board of DBV Technologies May 15, 2012 First quarter 2012 topline, scientific activity and upcoming clinical data May 10, 2012 DBV Technologies welcomes Charles Ruban as Chief Development Officer March 28, 2012 Successful Initial Public Offering (IPO) for DBV Technologies Page 47 of 49« First«...102030...4546474849»
